Almac Sciences, a member of the Almac Group, has been awarded a Life Sciences Innovative Manufacturing Fund (LSIMF) Grant to support the expansion of its small molecule active pharmaceutical ingredients (API) manufacturing facility at its Global Headquarters in Craigavon, UK.
The grant will support the installation of the expanded facility, already under construction, which is due for completion in Summer 2025.
Once complete, the 30,000 sqft facility will support small molecule API production.
Almac was one of two UK pharmaceutical companies awarded the grant to support manufacturing expansion projects. The Department for Science Innovation and Technology (DSIT) reopened the LSIMF in 2023 to support businesses investing in manufacturing projects in the UK.
Over its lifetime, the fund will provide capital grants for investments in the manufacture of human medicines (drug substance and drug product), medical diagnostics and MedTech products.
Almac Sciences has grown rapidly over the last five years and this expansion is part of a multi-million-pound investment programme to support increased client manufacturing demands.
The first stage of Almac’s GMP facility expansion was announced late 2022, with an extension to its current GMP manufacturing facility and warehouse expansion.
Increased capacity for peptide API production has just been announced, creating another manufacturing centre and further supporting the business’ ongoing growth plans.
Dr Daniel Bayston, VP Small Molecule API, said: “As a privately-owned and independent company, we are committed to re-investing all our profit back into the business, allowing us to continuously innovate and expand. We are delighted and grateful to be awarded this grant, assisting us with our ongoing expansion plans.
